Tip os
Log ind
Ritzau_40478744.jpg
Foto: Finn Frandsen/Ritzau/arkiv

Rebien: We have an attractive location lined up for EMA

Top picks in English:

If the European Medicines Agency (EMA) moves to Denmark, the Danish government has a location lined up. But negotiations are omngoing and the Government is keeping its options open, says its special envoy, Lars Rebien Sørensen.


BY MARTIN HAVTORN PETERSEN
Offentliggjort 31.05.17 kl. 22:23

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Danish biotech company sold to Swedes

sverige2.jpg Top picks in English:

The Swedish company Ascelia, managed by a former Sunstone director, has acquired the biotech company Oncoral and its cancer candidate, which is currently being tested in phase I trials at Herlev Hospital in Denmark.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Bavarian management shocked by phase III flop

Top picks in English:

Bavarian Nordic’s pivotal phase III study with the candidate Prostvac has turned out to be a flop. Surprising and shocking, says the CEO.

ALK chief: This is terrific data

Top picks in English:

Even Henrik Jacobi, ALK’s R&D chief, is surprised by the impact of the phase III data the company presented for a tree allergy tablet recently. The tablet can potentially enter the market in 2019.

MSD fined for employee’s LinkedIn post

Top picks in English:

Sharing product-related news on the social media LinkedIn had consequences for an employee in the Danish unit of MSD. The post could be regarded as advertisement and has resulted in a fine from The Ethical Committee for the Pharmaceutical Industry.

Leo Pharma announces new results for biologic hope

Top picks in English:

New phase III data from a study of one of Leo Pharma’s biologic drugs, Kyntheum, show significant benefits from long-term treatment with the drug.

Forsiden lige nu

ALK-topchef: Det kan ikke sammenlignes med Stallergenes

carstenhellmann.jpg Medicinal & Biotek:

Produktionsproblemerne på en fransk fabrik vil kun have en meget begrænset effekt på ALK's forretning og kan ikke sidestilles med den franske Rival Stallergenes' produktionskvaler i 2016, siger adm. direktør Carsten Hellmann. Det danske selskab er allerede i gang med en omfattende opgradering af kvalitetskontrol og compliance i sit globale produktionsapparat.

Analytiker: Bavarian-flop var ikke en overraskelse

Medicinal & Biotek:

Markedet burde ikke have været chokeret, da Bavarian Nordics Prostvac-forsøg fejlede, mener analytiker Peter Aabo. For forsøget har været stillet forkert op fra start.

Kinesisk biotekselskab henter en milliard på Nasdaq

Medicinal & Biotek:

Et kinesisk biotekselskab har gennemført en børsnotering på Nasdaq i USA og rejst en lille milliard kroner. Selskabets aktiepris strøg i vejret med 50 pct. på første handelsdag.

Danske Bank hæver anbefaling til Bavarian-aktien

Medicinal & Biotek:

Hos Danske Bank giver man nu Bavarian Nordic en smule opbakning efter selskabets bekymringer med det fejlede Prostvac-studie.

Novo Seeds-selskab mere end fordobler underskuddet

Medicinal & Biotek:

Det franske biotekselskab Lysogene har præsenteret sit første halvårsregnskab som børsnoteret virksomhed.

Franske problemer kan give uro i ALK-aktien

Medicinal & Biotek:

Selv om de økonomiske konsekvenser umiddelbart er til at overse, så kan det give uro i ALK-aktien, at vaccineselskabet er blevet tvunget til at lukke dele af produktionen på sin fabrik i Vandeuil i Frankrig.

ANNONCE
ANNONCE


ANNONCE